The vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.
“Currently, the biggest challenge is the time it takes to develop these treatments. The ability to manufacture cells in a day significantly decreases that time as well as the ability to do the release testing and to have a product ready in a week's time. That is a significant advance over the 3 to 4 weeks that it currently takes. That enables someone to get treatment without having to do bridging therapy... for oncology, for a disease that is rapidly dividing, people don't have that time, and it makes a big difference.”
Sid Kerkar, MD, vice president of oncology and research and development at Exuma Biotech, participated in a talk called “Subcutaneous generation of synthetic lymph nodes for the in vivo production of CAR-TaNK cells” at the 7th Annual CAR-TCR Summit 2022, held September 19-22 in Boston, Massachusetts.
CGTLive spoke with Kerkar to learn more about the chimeric antigen receptor T-cell natural killer (CAR-TaNK) cells being developed by Exuma Biotech to address current challenges with treating solid tumors. The therapy works by injecting CD3-directed lentiviral vectors loaded with peripheral blood mononuclear cells to form synthetic lymph nodes at the site of the injection that develop distinct CD3+ CD8+ CD56+ NKG2D+ CAR-TaNK cells. The therapy may allow for higher efficacy and lower toxicity, without the need for lymphodepletion chemotherapy. He also discussed other technology platforms in development at Exuma.